Skip to main content
Premium Trial:

Request an Annual Quote

Bellbrook Names Cambio UK Distributor for Transcreener Products

NEW YORK (GenomeWeb News) – BellBrook Labs today announced a revised distribution agreement with Cambio to include BellBrook's full Transcreener product line of HTS assays.

Under the terms of the revised deal, Cambio becomes the exclusive distributor of BellBrook's Transcreener HTS assays in the UK. Cambio will also distribute BellBrook's new Transzyme product line of turnkey methyltransferase assay kits combining precalibrated purified methytransferase enzymes and substrates from Reaction Biology with BellBrook's Transcreener Epigen Methyltransferase detection reagents.

BellBrook said the deal is its first granting exclusive distribution rights to a territory in Europe. Further financial and other terms were not disclosed.

The Transcreener HTS assays cover thousands of enzymes, including kinases, as well as emerging target families, such as methyltransferases, GTPases, and glycosyltransferases, BellBrook said, adding that the Transcreener assays are the only technology for direct detection of nucleotide enzyme products.

In March 2012, Cambio was named UK distributor for BellBrook's Transcreener HTS assays and iuvo Microconduit Array Platform.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.